GeneMedicine, Co. Ltd. is a research-based biotechnology company focused on developing and commercializing tumor-targeted and systemically deliverable oncolytic adenovirus for the treatment of intractable cancers. Our research programs utilize novel and innovative adenoviral vector platforms, which can selectively lyse cancer cells, express numerous combinations of therapeutic transgenes at a high level, induce robust antitumor immune response, and deliver systemically. The company’s key pipelines are based on oncolytic adenovirus against solid tumors (GM 101), pancreatic cancers (GM102), and metastatic lung and liver cancers (GM 103).
GeneMedicine’s key oncolytic adenovirus platforms leverage the unique characteristics, such as high gene transfer efficiency, viral replication capacity, and oncolytic activity, of adenovirus to maximize the anticancer effect. These state-of-the-art platforms are culmination of over two decades of extensive and rigorous research development process. Thus, these platforms possess several unique core technologies that supersede various aspects of competing viral platforms. Further, our major platforms possess unique set of therapeutic transgenes to offer specialized solution to various intractable cancer types. Importantly, we continue to perfect the cancer specificity, safety profile, therapeutic transgene expression, and antitumor effect of our platforms, striving to bring these innovative solutions to cancer patients worldwide and surpass the limitations of conventional therapies.